Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease.
Alzheimer's disease
drug repurposing
loop diuretics
pharmacoepidemiology
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
revised:
05
03
2024
received:
19
12
2023
accepted:
11
04
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
Bumetanide, a loop diuretic, was identified as a candidate drug for repurposing for Alzheimer's disease (AD) based on its effects on transcriptomic apolipoprotein E signatures. Cross-sectional analyses of electronic health records suggest that bumetanide is associated with decreased prevalence of AD; however, temporality between bumetanide exposure and AD development has not been established. We evaluated Medicare claims data using Cox proportional hazards regression to evaluate the association between time-dependent use of bumetanide and time to first AD diagnosis while controlling for patient characteristics. Multiple sensitivity analyses were conducted to test the robustness of the findings. We sampled 833,561 Medicare beneficiaries, 60.8% female, with mean (standard deviation) age of 70.4 (12). Bumetanide use was not significantly associated with AD risk (hazard ratio 1.05; 95% confidence interval, 0.99-1.10). Using a nationwide dataset and a retrospective cohort study design, we were not able to identify a time-dependent effect of bumetanide lowering AD risk. Bumetanide was identified as a candidate for repurposing for Alzheimer's disease (AD). We evaluated the association between bumetanide use and risk of AD. We used Medicare data and accounted for duration of bumetanide use. Bumetanide use was not significantly associated with risk of AD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : USC UCSD Epstein Family Alzheimer's Disease Research Collaboration
Investigateurs
Vahan Aslanyan
(V)
Anne Bang
(A)
Elizabeth Bevins
(E)
Gene L Bowman
(GL)
Ben Boyarko
(B)
Xu Chen
(X)
Claire D Clelland
(CD)
Hiroko H Dodge
(HH)
January Durant
(J)
Steve D Edland
(SD)
A Carol Evans
(AC)
Doug R Galasko
(DR)
William H Gerwick
(WH)
Barry D Greenberg
(BD)
Michelle Herman
(M)
Tatiana Herold
(T)
Vivian Hook
(V)
Diane M Jacobs
(DM)
Jeffrey Kaye
(J)
Doo Yeon Kim
(DY)
Edward H Koo
(EH)
Ken S Kosik
(KS)
Gabriel Léger
(G)
Jody-Lynn Lupo
(JL)
Karen Messer
(K)
Jeremiah D Momper
(JD)
Haakon B Nygaard
(HB)
Judy Pa
(J)
Luisa Quinti
(L)
Carolyn Revta
(C)
Jessica E Rexach
(JE)
Stacey J Sukoff Rizzo
(SJS)
Kevin D Rynearson
(KD)
Lon Schneider
(L)
Barbara Slusher
(B)
Rudolph E Tanzi
(RE)
Paul R Territo
(PR)
Jennifer S Yokoyama
(JS)
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010‐2015. Expert Opin Investig Drugs. 2017;26(6):735‐739.
Anderson RM, Hadjichrysanthou C, Evans S, Wong MM. Why do so many clinical trials of therapies for Alzheimer's disease fail? Lancet. 2017;390(10110):2327‐2329.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER‐ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512‐527.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9‐21.
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197‐210.
US Food and Drug Administration Press Release. FDA Converts Novel Alzheimer's disease Treatment to Traditional Approval. 2023. Accessed: October 01, 2023. https://www.fda.gov/news‐events/press‐announcements/fda‐converts‐novel‐alzheimers‐disease‐treatment‐traditional‐approval
Arbanas JC, Damberg CL, Leng M, et al. Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program. JAMA Intern Med. 2023;183(8):885‐889.
US Food and Drug Administration. Full Prescribing Information. 2023. Accessed November 20, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s000lbl.pdf
Ballard C, Aarsland D, Cummings J, et al. Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol. 2020;16(12):661‐673.
Delpire E, Terker AS, Gagnon KB. Pharmacology of Compounds Targeting Cation‐Chloride Cotransporter Physiology. Springer, Berlin, Heidelberg;2023.
Taubes A, Nova P, Zalocusky KA, et al. Experimental and real‐world evidence supporting the computational repurposing of bumetanide for APOE4‐related Alzheimer's disease. Nat Aging. 2021;1(10):932‐947.
Graber‐Naidich A, Lee J, Younes K, Greicius MD, Le Guen Y, He Z. Loop diuretics association with Alzheimer's disease risk. Front Aging. 2023;4:1211571.
Boyarko B, Podvin S, Greenberg B, et al. Evaluation of bumetanide as a potential therapeutic agent for Alzheimer's disease. Front Pharmacol. 2023;14:1190402.
Marcum ZA, Gabriel N, Bress AP, Hernandez I. Association of new use of antihypertensives that stimulate vs inhibit Type 2 and 4 angiotensin II receptors with dementia among medicare beneficiaries. JAMA Netw Open. 2023;6(1):e2249370.
Services CfMM. Centers for Medicare and Medicaid Services. Chronic Condition Data Warehouse. Chronic Conditions. 2013‐2023. Accessed May 12, 2024. https://www2.ccwdata.org/web/guest/condition-categories-chronic
Taylor DH, Jr., Fillenbaum GG, Ezell ME. The accuracy of Medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol. 2002;55(9):929‐937.
Canner JK, Giuliano K, Gani F, Schneider EB. Thirty‐day re‐admission after traumatic brain injury: Results from MarketScan®. Brain Inj. 2016;30(13‐14):1570‐1575.
Warwick J, Slavova S, Bush J, Costich J. Validation of ICD‐10‐CM surveillance codes for traumatic brain injury inpatient hospitalizations. Brain Inj. 2020;34(13‐14):1763‐1770.
Services CfMM. Billing and Coding: Cataract Surgery in Adults. 2024. Accessed February 2024. https://www.cms.gov/medicare‐coverage‐database/view/article.aspx?articleid=57195#:~:text=For%20Complex%20Cataract%20Surgery%20(CPT,perception%20of%20the%20surgical%20difficulty)
Eide MJ, Krajenta R, Johnson D, et al. Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol. 2009;171(1):123‐128.
Adelborg K, Horváth‐Puhó E, Ording A, Pedersen L, Sørensen HT, Henderson VW. Heart failure and risk of dementia: a Danish nationwide population‐based cohort study. Eur J Heart Fail. 2017;19(2):253‐260.
Sharp SI, Aarsland D, Day S, Sønnesyn H, Alzheimer's Society Vascular Dementia Systematic Review Group, Ballard C. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry. 2011;26(7):661‐669.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895‐e1032.
Kern DM, Cepeda MS, Lovestone S, Seabrook GR. Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications. Alzheimers Dement. 2019;5(1):862‐870.
de Havenon A, Anadani M, Prabhakaran S, Wong KH, Yaghi S, Rost N. Increased blood pressure variability and the risk of probable dementia or mild cognitive impairment: a post hoc analysis of the SPRINT MIND trial. J Am Heart Assoc. 2021;10(18):e022206.
Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19(3):24.
San‐Juan‐Rodriguez A, Zhang Y, He M, Hernandez I. Association of antidementia therapies with time to skilled nursing facility admission and cardiovascular events among elderly adults with Alzheimer disease. JAMA Netw Open. 2019;2(3):e190213.
Hernandez I, Divino V, Xie L, et al. A real‐world evaluation of primary medication nonadherence in patients with nonvalvular atrial fibrillation prescribed oral anticoagulants in the United States. Am J Cardiovasc Drugs. 2023;23(5):559‐572.
Hernandez I, Zhang Y, Brooks MM, Chin PK, Saba S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke. 2017;48(1):159‐166.